Get the Stockscreener App
0.9922
0.54%
0.0053
Pre-market:
1.01
0.0178
+1.79%
Senti Biosciences Holdings Inc stock is traded at $0.9922, with a volume of 259.02K.
It is up +0.54% in the last 24 hours and down -8.97% over the past month.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
See More
Previous Close:
$0.9869
Open:
$1
24h Volume:
259.02K
Relative Volume:
1.54
Market Cap:
$30.90M
Revenue:
$22,000
Net Income/Loss:
$-61.44M
P/E Ratio:
-0.3107
EPS:
-3.1938
Net Cash Flow:
$-43.64M
1W Performance:
+12.70%
1M Performance:
-8.97%
6M Performance:
-52.98%
1Y Performance:
-68.99%
1-Day Range:
$0.99
$1.02
1-Week Range:
$0.8629
$1.02
52-Week Range:
$0.7702
$3.8844
Senti Biosciences Holdings Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Holdings Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Holdings Inc
|
0.9922 | 30.74M | 22,000 | -61.44M | -43.64M | -3.1938 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Senti Biosciences Holdings Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | H.C. Wainwright | Buy |
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Holdings Inc Stock (SNTI) Latest News
Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR - Stock Titan
Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch - Bez Kabli
Senti Biosciences Inc. Q1 2026 Earnings: Narrowing Losses and Gene Circuitry ProgressCFO Commentary Report - Newser
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
Senti Biosciences Holdings, Inc.Common Stock (NQ: SNTI - The Chronicle-Journal
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure - TipRanks
SNTI Maintained by Chardan Capital -- Price Target Raised to $12 - GuruFocus
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - Sahm
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML - The Clinical Trial Vanguard
Senti Biosciences (NASDAQ: SNTI) flags going concern, lines up $40M convertible note financing - Stock Titan
Senti Biosciences Advances SENTI-202 to Pivotal Phase for AML, Secures $40M Financing, and Reports Reduced Q1 2026 Loss - Minichart
Senti Biosciences 1Q Loss $4.22M >SNTI - Moomoo
Senti Biosciences Advances SENTI-202 With New FDA Support - TipRanks
Senti Bio plans pivotal trial for AML therapy after FDA meeting - Investing.com
Senti Biosciences Holdings announces positive FDA RMAT meeting on registrational clinical and CMC strategy - marketscreener.com
Senti Bio plans pivotal trial for AML therapy after FDA meeting By Investing.com - Investing.com South Africa
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy - TradingView
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding - Stock Titan
Senti Biosciences 1Q Loss/Shr 14c >SNTI - Moomoo
SNTI Q1'26 Earnings: EPS estimate is (0.36) USD - TradingView
Number of shareholders of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
[15-12G] Senti Biosciences, Inc. SEC Filing - Stock Titan
Senti Biosciences Holdings, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SNTI | US8169441024 - marketscreener.com
Why Senti Biosciences (SNTI) looks attractive at current levels (Breakout Watch) 2026-05-06RSI Overbought Stocks - newser.com
Celadon backs Senti Biosciences (SNTI) with $40M notes and majority stake - Stock Titan
Senti Biosciences Secures Convertible Note Financing with Celadon - TipRanks
Senti Biosciences Holdings (NASDAQ: SNTI) continues $17.5M ATM program - Stock Titan
Senti Biosciences Strikes Up to $40 Million Secured Convertible Notes Financing With Celadon - TradingView
Celadon-led $40M notes could give Senti (NASDAQ: SNTI) majority holder - Stock Titan
Senti Biosciences 2025 Executive Compensation, Officer Employment Arrangements, and Stock Awards Overview - Minichart
[EFFECT] Senti Biosciences, Inc. SEC Filing - Stock Titan
Senti Biosciences (NASDAQ: SNTI) files 10-K/A on 2025 pay, board and ownership - Stock Titan
Senti Biosciences Holdings, Inc.: Financial Data Forecasts Estimates and Expectations | SNTI | US8169441024 - marketscreener.com
Senti Biosciences completes holding company reorganization, stock continues on Nasdaq - Investing.com Australia
Senti Biosciences (NASDAQ: SNTI) adopts S-3 post-merger reorganization - Stock Titan
Senti Biosciences Holdings (SNTI) adopts S-3 after April 24, 2026 merger - Stock Titan
Senti Biosciences (NASDAQ: SNTI) deregisters 8.7M shares previously for resale - Stock Titan
SNTI Senti Biosciences Inc. shares rise nearly 14 percent even as Q4 2025 EPS misses Wall Street estimates. - Cổng thông tin điện tử tỉnh Tây Ninh
Senti Biosciences (SNTI) Stock: Why You Should Avoid It (Bullish Sentiment) 2026-04-20Aggressive Growth Stocks - Xã Vĩnh Công
Senti Biosciences (SNTI) Stock 52-Week Low (Rocket Higher) 2026-04-18Community Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Senti Biosciences Q4 Operating Income USD -18 - Moomoo
[SCHEDULE 13D/A] Senti Biosciences, Inc. Amended Major Shareholder Report - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Bioscie - The National Law Review
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - Bitget
Cancer conference session will showcase Senti Bio's cell therapy approach - Stock Titan
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial - TradingView
Is Senti Biosciences (SNTI) Stock Trading at Fair Value | Price at $0.87, Up 1.55%Reversal Signals - Newser
Growth Review: Will Senti Biosciences Inc outperform small cap indexes2026 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
SNTI Q4 2025 Earnings: Senti Biosciences Inc. misses EPS estimates, no Q4 revenue - newser.com
Senti Biosciences Holdings Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):